Here are the latest items added to the CTN Dissemination Library for January – February 2025 (this post will be updated as new items come in): Predictors of Participation in Prenatal Substance Use Assessment, Counseling, and Treatment Among Pregnant Individuals in Prenatal Settings Who Use Cannabis. Lapham GT, et al. Journal of Addiction Medicine 2024 (in press). (CTN-0140) Optimizing Retention Strategies for Opioid Use Disorder Pharmacotherapy: The Retention Phase of the CTN-0100 Trial (RDD). Shulman M, et al. Contemporary Clinical Trials 2025;107816 (in press). (CTN-0100) Age, Period, and Cohort Effects in Alcohol and Other Substance Use: Implications for Health and Prevention (webinar). Keyes KM. Youth Special Interest Group (SIG) webinar, January 2025. Effects of Randomization to Buprenorphine or Naltrexone for OUD on Cannabis Use Outcomes: A Secondary Analysis of the X:BOT Trial. Shulman M, et al. Drug and Alcohol Dependence 2025 (in press). (CTN-0051) Evaluating Tests for Cluster-Randomized Trials with Few Clusters Under Generalized Linear Mixed Models with Covariate Adjustment: A Simulation Study. Qui H, et al. Statistics in Medicine 2024;43(2):201-215. Posted on January 19, 2025; Updated on February 11, 2025

Here are the latest items added to the CTN Dissemination Library for December 2024 -January 2024 (this post will be updated as new items come in): Willingness to Use Oral and Long-Acting Injectable PrEP in Substance-Using Men Who Have Sex with Men (SU-MSM) in High HIV Incidence Southern U.S. Cities: A NIDA Clinical Trials Network Study. Tross S, et al. AIDS and Behavior 2024 (in press). (CTN-0082 outcomes) HIV Prevention in Syringe Service Programs Since the Start of COVID-19: Where Do We Go From Here? Hatch MA, et al. Current HIV/AIDS Reports 2025;22:13. Cost-Effectiveness of Implementation Facilitation to Promote Emergency Department-Initiated Buprenorphine for Opioid Use Disorder. Lu T, et al. Annals of Emergency Medicine 2024 (in press). (CTN-0069) Racial and Ethnic Differences in Long-Term Outcomes Among Individuals with Opioid Use Disorder at Opioid Treatment Programs. Zhu Y, et al. Journal of Racial and Ethnic Health Disparities 2024 (in press). (CTN-0050) Data Cleaning and Harmonization of Clinical Trial Data: Medication-Assisted Treatment for Opioid Use Disorder. Balise RR, et al. PLoS ONE 2024;19(11):e0312695. (CTN-0027, CTN-0030, CTN-0051) Nurse Care Management of Opioid Use Disorder Treatment After 3 Years: A Secondary Analysis of the PROUD Cluster Randomized Clinical Trial. Lapham GT, et al. JAMA Network Open 2024;7(11):e2447447. (CTN-0074) Posted on January 7, 2025.

Here are the latest items added to the CTN Dissemination Library for November-December 2024 (this post will be updated as new items come in): Factors Associated with PrEP Awareness and Use Among Men Who Have Sex with Men Who Use Drugs in the Southern United States. Paschen-Wolff M, et al. AIDS Care 2024 (in press). (CTN-0082) Efficient and Flexible Mediation Analysis with Time-Varying Mediator, Treatments, and Confounders. Díaz I, Journal of Causal Inference 2023;11(1):20220077. (CTN-0051) Pharmacy-Based Preventive Services for Opioid Use Disorder: A Survey of U.S. Pharmacists. Wu L, et al. Addiction Science & Clinical Practice 2024;19:88. (primary outcomes for CTN-0105) CTN-0138: Adaptation, Implementation, and Cluster Randomized Trial of a Community Pharmacy-Based Prescription Drug Monitoring Program Opioid Risk Assessment Tool — A Protocol Paper. Cochran GT, et al. Addiction Science & Clinical Practice 2024;19:82. (CTN-0138) Artificial Intelligence-Based Drug Repurposing with Electronic Health Record Clinical Corroboration: A Case for Ketamine as a Potential Treatment for Amphetamine-Type Stimulant Use Disorder. Gao Z, et al. Addiction 2024 (in press). (CTN-0114) Posted November 18, 2024, updated December 18, 2024

Here are the latest items added to the CTN Dissemination Library for October-November 2024 (this post will be updated as new items come in): Machine Learning-Driven Analysis of Individualized Treatment Effects Comparing Buprenorphine and Naltrexone in Opioid Use Disorder Relapse Prevention. Afshar M, et al. Journal of Addiction Medicine 2024;18(5):511-519. (CTN-0051) Variation in Opioid Agonist Dosing in Clinical Trials by Race and Ethnicity. Ross RK, et al. JAMA Network Open 2024;7(10):e2436612. Sublingual Buprenorphine-Naloxone Compared With Injection Naltrexone for Opioid Use Disorder: Potential Utility of Patient Characteristics in Guiding Choice of Treatment. Nunes EV, et al. American Journal of Psychiatry 2021;178(7):660-671. (CTN-0051) Examination of Correlates of OUD Outcomes in Young Adults: Secondary Analysis From the XBOT Trial. Fishman M, et al. American Journal on Addiction 2021;30(5):433-444. (CTN-0051) Nonparametric Causal Mediation Analysis for Stochastic Interventional (In)direct Effects. Hejazi NS, et al. Biostatistics 2023;24(3):686-707. (CTN-0051) Polysubstance Use Before and During Treatment with Medication for Opioid Use Disorder: Prevalence and Association with Treatment Outcomes. Bunting AM, et al. Journal of Substance Abuse Treatment 2022;143:108830. (CTN-0051) Impact of Medication-Based Treatment on Health Care Utilization Among Individuals With Opioid Use Disorder. Gopaldas M, et al. Psychiatric Services 2023;74(12):1227-1233. (CTN-0051) Clinical and Psychosocial Outcomes by Sex Among Individuals Prescribed Buprenorphine-Naloxone (BUP-NX) or Extended-Release Naltrexone (XR-NTX) for Opioid Use Disorder. Paschen-Wolff M, et al. American Journal on Addiction 2023;32(6):584-592. (CTN-0051) Secondary Analysis of Agreement Between Negative Timeline Follow Back Report and Negative Urine Toxicology in a Large Trial of Individuals with Opioid Use Disorder. Shulman M, et…

Here are the latest items added to the CTN Dissemination Library for September– October 2024 (this post will be updated as new items come in): Falling Through the Cracks: The Struggle of Adolescents with Opioid Use Disorder in the Face of Limited Treatment Options. Kaliamurty S. Youth Special Interest Group (SIG) webinar, September 2024. Changes in Prenatal Cannabis Use Among Pregnant Individuals From 2012 to 2022. Young-Wolff KC, et al. Obstetrics & Gynecology 2024;144(4):e101-e104. (CTN-0104) Effectiveness of a Vaping Cessation Text Message Program Among a Diverse and High-Risk Sample of Adolescent E-Cigarette Users (webinar recording). Graham AL. Youth Special Interest Group (SIG) webinar, September 2024. Peer Intervention to Link Overdose Survivors to Treatment (PILOT): Protocol for a Multisite, Randomized Controlled Trial Conducted Within the National Institute on Drug Abuse Clinical Trials Network. Papa C, et al. JMIR Research Protocols 2024;13:e60277. (CTN-0107)

Here are the latest items added to the CTN Dissemination Library for July – August 2024 (this post will be updated as new items come in): Performance of the Tobacco, Alcohol, Prescription Medication, and Other Substance Use (TAPS) Tool in Screening Older Adults for Unhealthy Substance Use. Han BH, et al. Journal of Addiction Medicine 2024 (in press). (CTN-0059) Analyzing Quality of Life Among People with Opioid Use Disorder from the National Institute on Drug Abuse Data Share Initiative: Implications for Decision Making. Patton T, et al. Quality of Life Research 2024 (in press). (multiple protocols) Delivering MOUD to the Underserved: How Can Pharmacies Really Help? Gustafson DH, et al. Journal of Studies on Alcohol and Drugs 2024 (in press). (CTN-0124 Primary Outcomes) High Suicidality Predicts Overdose Events Among People with Substance Use Disorder: A Latent Class Analysis. Schmidt RD, et al. Frontiers in Public Health 2023;11:1150062. (multiple protocols) Association of Psychiatric and Substance Use Disorders with Cannabis Use and Cannabis Use Disorder During Early Pregnancy in Northern California. Young-Wolff KC, et al. Addiction 2024 (in press). (CTN-0140) Psychosocial Factors Linked to Uncontrolled Infection and Mortality Among People Living with HIV Who Use Substances: A Latent Class Analysis. Schmidt RD, et al. AIDS and Behavior 2024 (in press). (CTN-0049, CTN-0064) Suicide and Cannabis Use Among Youth & Young Adults. Hammond CJ & Hinckley JD. CTN Youth Special Interest Group (SIG) webinar, July 2024 Discriminative Validity of a Substance Use Symptom Checklist for Moderate-Severe DSM-5 Cannabis Use Disorder (CUD) in…

The primary outcomes paper for CTN-0124, Assessment and Design of a Cost-Effective Collaborative MOUD Delivery System, is now available! Citation: Gustafson DH, Molfenter T, Kunes T, Langdon L, Koplin M, Parker F, Branny K, Ghitza U, Bart G. Delivering MOUD to the Underserved: How Can Pharmacies Really Help? Journal of Studies on Alcohol and Drugs 2024 (in press). What’s the question? Access to treatment for opioid use disorder (OUD) is a challenge in rural settings and for communities of color, partly because of the limited availability of healthcare providers equipped and willing to provide medications for OUD (MOUD). Pharmacies have been increasingly proposed as one way to enhance access to MOUD, as they are often more available in rural and other underserved communities than primary care physicians or other prescribers. A key question, however, is whether or not pharmacies are adequately prepared to distribute medications and other resources to people with OUD. This study aimed to answer that question by examining the potential role of pharmacies in MOUD delivery, looking at what barriers exist, and proposing actionable strategies for improvement. How was this study conducted? To address this issue, the CTN-0124 study team developed a 9-month engineering systems analysis, a problem-solving approach that breaks a system into its individual parts, analyzes how well those parts work together to accomplish their purpose, and creates an aspirational design for the future. To perform this analysis, the study team, made up of 5 systems analysis (3 from health care and 2 from…

Here are the latest items added to the CTN Dissemination Library for June – July 2024 (this post will be updated as new items come in): Extended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid Withdrawal. D’Onofrio G, et al. JAMA Network Open 2024;7(7):e2420702. The Potential Impact of Clinical Decision Support on Nonwaivered Primary Care Clinicians’ Prescribing of Buprenorphine. Olson AW, et al. Health Affairs Scholar 2023;1(4):qxad051. CTN-0076-Ot Barriers and Facilitators to Using a Clinical Decision Support Tool for Opioid Use Disorder in Primary Care: Insights from Clinicians and Clinic Leaders. Hooker SA, et al. Journal of the American Board of Family Medicine 2024 (in press). CTN-0076-Ot Assessing Substance Use Disorder Symptoms with a Checklist among Primary Care Patients with Opioid Use Disorder and/or Long-Term Opioid Treatment: An Observational Study. Williams EC, et al. Journal of General Internal Medicine 2024 (in press). CTN-0113 Predictability of Buprenorphine-Naloxone Treatment Retention: A Multi-Site Analysis Combining Electronic Health Records and Machine Learning. Haredasht FN, et al. Addiction 2024 (in press). CTN-0136 Predictors of Urine Toxicology and Other Biologic Specimen Missingness in Randomized Trials of Substance Use Disorders. Kelley AT, et al. Drug and Alcohol Dependence 2024;261:111368. (multiple protocols)

Here are the latest items added to the CTN Dissemination Library for May – June 2024 (this post will be updated as new items come in): “To prescribe or not to prescribe, that is the question”: Perspectives on opioid prescribing for chronic, cancer-related pain from clinicians who treat pain in survivorship. Bulls HW, et al. Cancer. 2024 Apr 3. doi: 10.1002/cncr.35299. PMID: 38567685. CTN-0115 Substance Use Among Black Adolescents – Maximizing Strengths and Overcoming Barriers in Substance Use Prevention. Aneni K. Youth Special Interest Group (SIG) webinar, May 2024. Wiidookaage’win: Beta-test of a Facebook Group Intervention for Native Women to Support Opioid Use Recovery. Roche AI, et al. Journal of Substance Use and Addiction Treatment 2024;163:209396. Discontinuation of Medication Treatment for Opioid Use Disorder After a Successful Course: The Discontinutaion Phase of the CTN-0100 (RDD) Trial. Discontinuation of Medication Treatment for Opioid Use Disorder After a Successful Course: The Discontinutaion Phase of the CTN-0100 (RDD) Trial. Shulman M, et al. Contemporary Clinical Trials 2024;142:107543. CTN-0100 Addiction Medicine Treatment Utilization by Race/Ethnicity Among Adolescents with Substance Use Problem Before Versus During the COVID-19 Pandemic. Palzes VA, et al. Journal of Adolescent Health 2024;74(6):1260-1263. CTN-0117 Overall and Telehealth Addiction Treatment Utilization by Age, Race, Ethnicity, and Socioeconomic Status in California After COVID-19 Policy Changes. Palzes VA, et al. JAMA Health Forum 2023;4(5):e231018. CTN-0117